OR WAIT 15 SECS
Vico Therapeutics has raised $31 million (€27 million) in a Series A financing round, which the company will use to further advance its Antisense OligoNucleotides lead platform.
Dutch biotech, Vico Therapeutics, has raised $31 million (€27 million) in a Series A financing round, which the company will use to further advance its Antisense OligoNucleotides (AON) lead platform.
The AON platform is focused on the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021. Additionally, the company’s early discovery RNA editing platform is directed towards RETT syndrome.
“This Series A funding will allow us to advance our lead program into the clinic and continue to build our capabilities as a leader in the development of novel therapies for serious CNS disorders,” said Luc Dochez, founder and chairman of Vico Therapeutics, in the press release. “We see tremendous potential to advance the field and apply the breadth of our AON expertise to address severe neurological disorders. We are looking forward to accelerating the development of our platform technologies around AON technology and RNA-modulation/editing to bring best-in-class therapies to patients. The Vico team built this company around a unique synergy between state-of-the-art molecular biology, AON chemistry laboratories and industry experience in successfully developing drugs based on AON technology.”
Source: Vico Therapeutics